View Older Stories View More Recent Stories

Aug 21, 2025 07:01AM Evoke Pharma patent for GIMOTI nasal spray added to FDA Orange Book
Aug 21, 2025 07:00AM Evoke Pharma Announces Listing of New GIMOTI® Patent in FDA Orange Book
Aug 14, 2025 07:00AM Evoke Pharma Reports Second Quarter 2025 Financial Results and Provides Business Update
Aug 6, 2025 06:31AM Evoke Pharma receives patent extending GIMOTI exclusivity to 2038
Aug 6, 2025 06:30AM Evoke Pharma Announces Issuance of New U.S. Patent for GIMOTI With Extended Exclusivity to Late 2038
Jul 9, 2025 08:17AM Evoke Pharma gets patent approval extending GIMOTI protection to 2036
Jul 9, 2025 08:16AM Evoke Pharma Receives Notice of Allowance for U.S. Patent Application for GIMOTI Extending Orange Book listings to 2036
May 13, 2025 04:05PM Evoke Pharma Reports First Quarter 2025 Financial Results and Provides Business Update
Apr 28, 2025 08:30AM Evoke Pharma to Present New Data Comparing Tardive Dyskinesia Incidence in Continuous vs Intermittent Metoclopramide Use at DDW 2025
Mar 13, 2025 04:02PM Evoke Pharma, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Mar 6, 2025 08:30AM Evoke Pharma to Report Fourth Quarter and Full Year 2024 Results on March 13, 2025
Feb 24, 2025 08:31AM Evoke Pharma (EVOK) Appoints Greg Pyszczymuka to its Board
Feb 24, 2025 08:30AM Evoke Pharma Announces the Appointment of Greg Pyszczymuka to the Board of Directors
Dec 19, 2024 08:30AM Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends
Nov 7, 2024 04:05PM Evoke Pharma, Inc. Reports Third Quarter 2024 Financial Results
Oct 28, 2024 07:01AM Evoke Pharma (EVOK) and EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users
Oct 28, 2024 07:00AM Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
Oct 28, 2024 07:00AM Evoke Pharma & EVERSANA Announce Statistically Significant Improvement in Patient Outcomes for GLP-1 users with Diabetic Gastroparesis using GIMOTI®
Oct 23, 2024 08:30AM Evoke Pharma to Showcase Award-Winning Research at the 2024 American College of Gastroenterology Annual Scientific Meeting
Oct 22, 2024 08:31AM Evoke Pharma (EVOK) Appoints Ben Smeal to its Board
Oct 22, 2024 08:30AM Evoke Pharma Announces the Appointment of Ben Smeal to the Board of Directors
Oct 1, 2024 08:30AM Evoke Pharma (EVOK) Receives $3M in Proceeds from Existing Warrants
Oct 1, 2024 08:30AM Evoke Pharma Announces Proceeds from Existing Warrants and Board Expansion
Sep 19, 2024 02:21PM Evoke Pharma (EVOK) Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Sep 19, 2024 02:20PM Evoke Pharma Reaffirms Its Commitment to Patients with Gastroparesis Amid Industry Developments
Sep 9, 2024 08:30AM Evoke Pharma to Participate in Gastroenterology and Hepatology Advanced Practice Providers (GHAPP) Annual Conference
Sep 4, 2024 09:20AM Evoke Pharma to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
Aug 13, 2024 08:00AM Evoke Pharma, Inc. Reports Second Quarter 2024 Financial Results
Aug 8, 2024 08:30AM Evoke Pharma, Inc. Supports Gastroparesis Awareness Month
Jun 17, 2024 08:31AM Evoke Pharma (EVOK) Reports Commercial Strategy Progress for GIMOTI
Jun 17, 2024 08:30AM Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
Jun 17, 2024 08:30AM Evoke Pharma Reports Commercial Strategy Progress & Positive Momentum for GIMOTI
May 14, 2024 04:15PM Evoke Pharma Reports First Quarter 2024 Financial Results
Apr 17, 2024 08:30AM Evoke Pharma to Host Virtual Key Opinion Leader (KOL) Webinar on the Evolving Landscape of Gastroparesis: GIMOTI, Hospitalizations, and GLP-1 Medications
Mar 21, 2024 04:16PM Evoke Pharma (EVOK) Appoints Matthew J. D’Onofrio as CEO
Mar 21, 2024 04:15PM Evoke Pharma Announces Senior Leadership Transition with Promotion of Matthew J. D’Onofrio to Chief Executive Officer
Mar 14, 2024 04:05PM Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results
Mar 7, 2024 04:10PM Evoke Pharma to Report Fourth Quarter and Full Year 2023 Results on March 14, 2024
Nov 27, 2023 08:30AM Evoke Pharma (EVOK) Announces FDA Orange Book Listing of New GIMOTI Patent
Nov 27, 2023 08:30AM Evoke Pharma Announces FDA Orange Book Listing of New GIMOTI Patent
Nov 14, 2023 08:30AM United States Patent and Trademark Office (USPTO) Grants Another Formulation Patent Covering GIMOTI
Nov 9, 2023 08:30AM Evoke Pharma Reports Third Quarter 2023 Financial Results
Oct 18, 2023 08:30AM Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presen
Sep 14, 2023 08:32AM Evoke Pharma (EVOK) Receives Notice of Allowance from USPTO for GIMOTI
Sep 14, 2023 08:30AM Evoke Pharma Receives Notice of Allowance from USPTO for GIMOTI®
Aug 10, 2023 08:30AM Evoke Pharma Reports Second Quarter 2023 Financial Results
Aug 7, 2023 08:30AM Evoke Pharma and EVERSANA Announce Abstract Acceptance at 2023 American Neurogastroenterology and Motility Society (ANMS) Meeting
Jul 25, 2023 08:30AM Evoke Pharma and EVERSANA Announce Abstract Selection for Plenary Oral Presentation at The American College of Gastroenterology (ACG) 2023 Annual Meeting
Jun 14, 2023 08:30AM Evoke Pharma to Host First Key Opinion Leader Webinar on Healthcare Resource Utilization Data Related to Gastroparesis and its Treatment
May 15, 2023 04:05PM Evoke Pharma Reports First Quarter 2023 Financial Results
View More Recent Stories View Older Stories